Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Rev Esp Quimioter ; 35(3): 241-248, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35298111

ABSTRACT

OBJECTIVE: Influenza vaccination is an effective way of reducing the burden of seasonal influenza. Chicken egg embryos are the most common source of influenza vaccines, but cell culture production has emerged as an alternative that could be advantageous. This article reviews the available literature on the efficacy/effectiveness of cell culture-based influenza vaccines compared with egg-based vaccines. METHODS: We conducted a review of the actual literature and analyzed those studies comparing the effectiveness of cell culture-based and egg-based vaccines in the last ten years. RESULTS: Eight studies were analyzed; 1 was a clinical trial and 7 were retrospective cohort studies. The clinical trial found no significant differences in the efficacy of both vaccines with respect to placebo. The results of the observational studies were inconsistent and relative effectiveness varied among studies, even though most were performed during the same season, and in some cases, in the same region and using the same data records. Furthermore, in most studies, the comparisons between vaccines were not statistically significant. CONCLUSIONS: There is insufficient evidence that cell culture-based vaccines are superior to egg-based vaccines in terms of efficacy/effectiveness.


Subject(s)
Influenza Vaccines , Influenza, Human , Cell Culture Techniques , Humans , Influenza Vaccines/therapeutic use , Influenza, Human/drug therapy , Influenza, Human/prevention & control , Retrospective Studies , Vaccination
2.
Semergen ; 47(6): 411-425, 2021 Sep.
Article in Spanish | MEDLINE | ID: mdl-34332864

ABSTRACT

Community-acquired pneumonia (CAP) continues to be an important cause of morbidity and mortality in adults. The aim of this study is to update the practical prevention guide for CAP through vaccination in Spain developed in 2016 and updated in 2018, based on available vaccines and evidence through bibliographic review and expert opinion. The arrival of COVID-19 as a new cause of CAP and the recent availability of safe and effective vaccines constitutes the most significant change. Vaccines against pneumococcus, influenza, pertussis and COVID-19 can help to reduce the burden of disease from CAP and its associated complications. The available evidence supports the priority indications established in this guide, and it would be advisable to try to achieve a widespread dissemination and implementation of these recommendations in routine clinical practice.


Subject(s)
COVID-19 , Community-Acquired Infections , Pneumonia, Pneumococcal , Adult , Community-Acquired Infections/prevention & control , Humans , Pneumococcal Vaccines , Pneumonia, Pneumococcal/prevention & control , SARS-CoV-2 , Vaccination
4.
BMC Infect Dis ; 19(1): 973, 2019 Nov 15.
Article in English | MEDLINE | ID: mdl-31730464

ABSTRACT

BACKGROUND: Diabetes is one of the underlying risk factors for developing community-acquired pneumonia (CAP). The high prevalence of diabetes among population and the rising incidence of this illness, converts it as an important disease to better control and manage, to prevent its secondary consequences as CAP. The objective of this research is to describe the characteristics of the patients with diabetes and the differences with the no diabetes who have had an episode of CAP in the context of the primary care field. METHODS: A retrospective, observational study in adult patients (> 18 years-old) who suffer from CAP and attended at primary care in Spain between 2009 and 2013 was developed using the Computerized Database for Pharmacoepidemiological Studies in Primary Care (BIFAP). We carried out a descriptive analysis of the first episodes of CAP, in patients with or without diabetes as comorbidity. Other morbidity (CVA, Anaemia, Arthritis, Asthma, Heart disease, Dementia, Depression, Dysphagia, Multiple sclerosis, Epilepsy, COPD, Liver disease, Arthrosis, Parkinson's disease, Kidney disease, HIV) and life-style factors were also included in the study. RESULTS: A total of 51,185 patients were included in the study as they suffer from the first episode of CAP. Of these, 8012 had diabetes as comorbidity. There were differences between sex and age in patients with diabetes. Patients without diabetes were younger, and had less comorbidities including those related to lifestyles such as smoking, alcoholism, social and dental problems than patients with diabetes. CONCLUSIONS: Patients who developed an episode of CAP with diabetes have more risk factors which could be reduced with an appropriate intervention, including vaccination to prevent successive CAP episodes and hospitalization. The burden of associated factors in these patients can produce an accumulation of risk. Health care professional should know this for treating and control these patients in order to avoid complications. Diabetes and those other risk factors associated could be reduced with an appropriate intervention, including vaccination to prevent the first and successive CAP episodes and the subsequent hospitalization in severe cases.


Subject(s)
Community-Acquired Infections/diagnosis , Diabetes Complications/diagnosis , Pneumonia/diagnosis , Age Factors , Aged , Aged, 80 and over , Community-Acquired Infections/complications , Comorbidity , Diabetes Complications/complications , Female , Humans , Life Style , Male , Middle Aged , Pneumonia/complications , Primary Health Care , Retrospective Studies , Risk Factors , Sex Factors , Spain
5.
Rehabilitacion (Madr) ; 53(1): 43-55, 2019.
Article in Spanish | MEDLINE | ID: mdl-30929831

ABSTRACT

INTRODUCTION: Intra-articular ozone infiltrations have been used as a therapeutic intervention in osteoarthritis of the knee with reports of favourable effects. However, this therapeutic procedure is still controversial due to the lack of scientific evidence to justify its use. OBJECTIVE: To evaluate the safety and efficacy of intra-articular ozone infiltrations in patients with knee osteoarthritis. MATERIAL AND METHODS: A systematic search was performed in electronic databases such as Pubmed, Dialnet, Scielo, Medigraphic and other electronic sources from January 1990 to January 2018. We included controlled clinical trials that used intra-articular ozone infiltrations as a therapeutic intervention in patients with knee osteoarthritis. The variables analysed were the study design, risk of bias, clinical configuration, characteristics of the participants, characteristics of the interventions, results, length of follow-up and adverse events. RESULTS: Ten studies with a total of 400 patients treated with ozone vs 381 controls were included in the systematic review. Most studies had a high risk of bias. Intra-articular ozone infiltrations were more effective than placebo and were as effective as other interventional treatments in short-term follow-up. No adverse effects or serious adverse reactions were reported in the treated patients. CONCLUSION: Intra-articular ozone infiltration appears to be an effective therapeutic intervention in the short term. However studies with better methodological quality are needed to confirm its efficacy and to analyze long-term safety.


Subject(s)
Osteoarthritis, Knee/therapy , Ozone/administration & dosage , Humans , Injections, Intra-Articular , Osteoarthritis, Knee/pathology , Ozone/adverse effects , Research Design , Treatment Outcome
8.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 44(8): 590-597, nov.-dic. 2018. tab
Article in Spanish | IBECS | ID: ibc-181273

ABSTRACT

La neumonía adquirida en la comunidad (NAC) continúa siendo una causa importante de morbimortalidad en adultos. El objetivo de este documento es actualizar la guía práctica de prevención de la NAC mediante vacunación en España desarrollada en 2016 en función de las vacunas y evidencias disponibles mediante revisión bibliográfica y opinión de expertos. Las vacunas frente al neumococo y la gripe continúan siendo las principales herramientas preventivas disponibles frente a la NAC, y pueden contribuir a disminuir la carga de enfermedad por NAC y sus complicaciones asociadas. La evidencia disponible avala las indicaciones prioritarias establecidas en esta guía, y sería recomendable tratar de lograr una difusión e implementación amplia en la práctica clínica rutinaria de estas recomendaciones


Community-acquired pneumonia (CAP) continues to be an important cause of morbidity and mortality in adults. The aim of this study is to update the 2016 practical prevention guidelines for CAP through vaccination in Spain, based on the available vaccines, as well as the evidence using a literature review and expert opinion. Vaccines against pneumococcus and influenza continue to be the main prevention tools available against CAP, and can contribute to reduce the burden of disease due to CAP and its associated complications. The available evidence supports the priority indications established in these guidelines, and it would be advisable to try to achieve a widespread dissemination and implementation of these recommendations in routine clinical practice


Subject(s)
Humans , Adult , Influenza Vaccines/administration & dosage , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Community-Acquired Infections/prevention & control , Pneumonia, Pneumococcal/epidemiology , Practice Guidelines as Topic , Spain
9.
Semergen ; 44(8): 590-597, 2018.
Article in Spanish | MEDLINE | ID: mdl-30318406

ABSTRACT

Community-acquired pneumonia (CAP) continues to be an important cause of morbidity and mortality in adults. The aim of this study is to update the 2016 practical prevention guidelines for CAP through vaccination in Spain, based on the available vaccines, as well as the evidence using a literature review and expert opinion. Vaccines against pneumococcus and influenza continue to be the main prevention tools available against CAP, and can contribute to reduce the burden of disease due to CAP and its associated complications. The available evidence supports the priority indications established in these guidelines, and it would be advisable to try to achieve a widespread dissemination and implementation of these recommendations in routine clinical practice.


Subject(s)
Influenza Vaccines/administration & dosage , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Adult , Community-Acquired Infections/prevention & control , Humans , Influenza, Human/prevention & control , Pneumonia, Pneumococcal/epidemiology , Practice Guidelines as Topic , Spain
10.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 36(4): 260-262, jul.-ago. 2017. ilus
Article in Spanish | IBECS | ID: ibc-163745

ABSTRACT

Se presenta el caso de una niña de 3 años pluripatológica, con una enfermedad genética mitocondrial (encefalomiopatía necrosante subaguda o síndrome de Leigh), insuficiencia renal crónica estadio v por una esclerosis mesangial difusa y alteraciones del desarrollo, que fue diagnosticada de hipertiroidismo autoinmune por enfermedad de Graves-Basedow. A las 6 semanas del inicio terapéutico con neocarbimazol, la paciente presentó un cuadro de agranulocitosis severa que obligó a suspender la medicación con fármacos antitiroideos, motivo por el cual fue tratada de manera eficaz con terapia metabólica con 131I. La relevancia del artículo radica en la infrecuencia de la enfermedad de Graves en niños prepuberales (especialmente menores de 6 años), las complicaciones en el desarrollo derivadas de un posible diagnóstico tardío, la aparición de agranulocitosis como efecto adverso potencialmente grave tras el uso de antitiroideos y los pocos casos reportados de terapia ablativa con 131I a esta edad, que otorgan singularidad al caso (AU)


The case is presented of a 3 year-old girl with mitochondrial disease (subacute necrotizing encephalomyelopathy of Leigh syndrome), v-stage chronic kidney disease of a diffuse mesangial sclerosis, as well as developmental disorders, and diagnosed with hyperthyroidism Graves-Basedow disease. Six weeks after starting the treatment with neo-carbimazole, the patient reported a serious case of agranulocytosis. This led to stopping the anti-thyroid drugs, and was treated successfully with 131I ablation therapy. The relevance of the article is that Graves’ disease is uncommon in the paediatric age range (especially in children younger than 6 years old), and developing complications due to a possible late diagnosis. Agranulocytosis as a potentially serious adverse effect following the use of anti-thyroid drugs, and the few reported cases of ablation therapy with 131I at this age, makes this case unique (AU)


Subject(s)
Humans , Female , Child, Preschool , Graves Disease/complications , Graves Disease , Agranulocytosis/complications , Agranulocytosis , Antithyroid Agents/adverse effects , Iodine Radioisotopes/therapeutic use , Graves Disease/therapy , Radionuclide Imaging , Sodium Pertechnetate Tc 99m/administration & dosage , Sodium Pertechnetate Tc 99m/analysis , Thyroid Gland/pathology , Thyroid Gland , Comorbidity
11.
Rev Esp Med Nucl Imagen Mol ; 36(4): 260-262, 2017.
Article in English, Spanish | MEDLINE | ID: mdl-28392335

ABSTRACT

The case is presented of a 3 year-old girl with mitochondrial disease (subacute necrotizing encephalomyelopathy of Leigh syndrome), v-stage chronic kidney disease of a diffuse mesangial sclerosis, as well as developmental disorders, and diagnosed with hyperthyroidism Graves-Basedow disease. Six weeks after starting the treatment with neo-carbimazole, the patient reported a serious case of agranulocytosis. This led to stopping the anti-thyroid drugs, and was treated successfully with 131I ablation therapy. The relevance of the article is that Graves' disease is uncommon in the paediatric age range (especially in children younger than 6 years old), and developing complications due to a possible late diagnosis. Agranulocytosis as a potentially serious adverse effect following the use of anti-thyroid drugs, and the few reported cases of ablation therapy with 131I at this age, makes this case unique.


Subject(s)
Agranulocytosis/chemically induced , Antithyroid Agents/adverse effects , Carbimazole/adverse effects , Graves Disease/radiotherapy , Iodine Radioisotopes/therapeutic use , Agranulocytosis/therapy , Antithyroid Agents/therapeutic use , Blood Transfusion , Carbimazole/therapeutic use , Child, Preschool , Developmental Disabilities/complications , Drug Therapy, Combination , Female , Graves Disease/complications , Graves Disease/drug therapy , Humans , Leigh Disease/complications , Nephrotic Syndrome/complications , Propranolol/therapeutic use , Sclerosis/complications
14.
Rehabilitación (Madr., Ed. impr.) ; 50(4): 267-270, oct.-dic. 2016. ilus
Article in Spanish | IBECS | ID: ibc-158691

ABSTRACT

Se presenta el caso de una paciente de 41 años que se diagnostica de flebolinfedema primario con localización en miembro superior izquierdo asociado a síndrome de Klippel-Trénaunay, que no presentó manifestación clínica hasta los 37 años de edad, momento de aparición de la tríada clínica característica de angiomas cutáneos, varicosidades e hipertrofia de los tejidos blandos. La relevancia de este artículo radica en que se trata de una enfermedad rara y congénita, que se manifiesta en la infancia o adolescencia, con afectación más frecuente en miembros inferiores. Su etiopatogenia es aún desconocida, surgiendo casos esporádicos, aunque se cree que podría ser debido a una alteración en el desarrollo del mesodermo en el feto, que afecta a las líneas angioblásticas, linfoblásticas y osteoblásticas. Es importante conocer los diferentes signos clínicos para un diagnóstico y tratamiento precoz, el cual suele ser sintomático y la rehabilitación constituye un pilar fundamental dentro del tratamiento multidisciplinar (AU)


The case is presented of a 41 years old patient with primary lymphedema diagnostic in her left upper limb associated with Klippel-Trénaunay syndrome, who did not present any clinical manifestations until 37 years old, time of appearance of the characteristic clinical triad of cutaneous angiomatosis, varicose veins and hypertrophy. The relevance of this article is that it is a rare and congenital disease. This syndrome usually manifests in childhood or adolescence with more frequent involvement of the lower limbs. Its etiopathogeny is still unexplained, emerging sporadic cases, although it is believed it could be due to fetal's mesoderm development alteration, which affecting angioblastic, lymphoblastoid and osteoblastic lines. The importance of an early correct diagnosis and its symptomatic treatment, where rehabilitation has a fundamental role within the multidisciplinary approach is emphasized (AU)


Subject(s)
Humans , Female , Adult , Lymphedema/complications , Lymphedema/diagnosis , Lymphedema/rehabilitation , Klippel-Feil Syndrome/complications , Early Diagnosis , Hypertrophy/complications , Massage , Drainage/methods , Lymphedema/physiopathology , Lymphedema , Radionuclide Imaging/instrumentation , Radionuclide Imaging/methods , Upper Extremity/physiopathology , Upper Extremity
15.
BMC Infect Dis ; 16(1): 645, 2016 11 07.
Article in English | MEDLINE | ID: mdl-27821085

ABSTRACT

BACKGROUND: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in adults even in developed countries. Several lifestyle factors and comorbidities have been linked to an increased risk, although their prevalence has not been well documented in the primary care setting. The aim of this study is to assess the incidence, risk factor and comorbid conditions distribution of CAP in adults in primary care in Spain. METHODS: Retrospective observational study in adults (>18 years-old) with CAP diagnosed and attended at primary care in Spain between 2009 and 2013, using the Computerized Database for Pharmacoepidemiological Studies in Primary Care (BIFAP). RESULTS: Twenty-eight thousand four hundred thirteen patient records were retrieved and analyzed. Mean age (standard deviation): 60.5 (20.3) years, 51.7 % males. Global incidence of CAP in adults was estimated at 4.63 per 1000 persons/year. CAP incidence increased progressively with age, ranging from a 1.98 at 18-20 years of age to 23.74 in patients over 90 years of age. According to sex, global CAP incidence was slightly higher in males (5.04) than females (4.26); CAP incidence from 18 to 65 year-olds up was comparable between males (range: 2.18-5.75) and females (range: 1.47-5.21), whereas from 65 years of age, CAP incidence was noticeable higher in males (range: 7.06-36.93) than in females (range: 5.43-19.62). Average prevalence of risk factors was 71.3 %, which increased with age, doubling the risk in males by the age of 75 (females 20 % vs males 40 %). From 55 years of age, at least one risk factor was identified in 85.7 % of cases: one risk factor (23.8 %), two risk factors (23.4 %), three or more risk factors (38.5 %). Major risk factors were: metabolic disease (27.4 %), cardiovascular disease (17.8 %) and diabetes (15.5 %). CONCLUSIONS: The annual incidence of CAP in primary care adults in Spain is high, comparable between males and females up to 65 years of age, but clearly increasing in males from that age. CAP risk increases with age and doubles in males older than 75 years. The majority of CAP cases in patients over 55 years of age is associated to at least one risk factor. The main risk factors associated were metabolic disease, cardiovascular disease, and diabetes.


Subject(s)
Pneumonia/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/epidemiology , Community-Acquired Infections/epidemiology , Developed Countries , Female , Humans , Incidence , Life Style , Male , Medical Records , Metabolic Diseases/epidemiology , Middle Aged , Prevalence , Primary Health Care , Retrospective Studies , Risk Factors , Spain/epidemiology , Young Adult
16.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 42(7): 464-475, oct. 2016. tab
Article in Spanish | IBECS | ID: ibc-156673

ABSTRACT

Introducción. La neumonía adquirida en la comunidad (NAC) es una causa importante de morbimortalidad en adultos. La incidencia anual de NAC en adultos en España varía entre 3 y 14 casos por 1.000 habitantes. Las guías clínicas actuales se centran básicamente en el abordaje terapéutico de la NAC más que en su prevención. El objetivo de este estudio es desarrollar y proponer una guía práctica de prevención de la NAC mediante vacunación en España en función de las vacunas y las evidencias disponibles. Métodos. Revisión bibliográfica y opinión de expertos. Resultados. Las vacunas contra el neumococo y la gripe son las principales herramientas preventivas disponibles frente a la NAC. La edad, las enfermedades crónicas y la inmunosupresión son factores de riesgo para la neumonía, por lo que estas poblaciones deben ser objetivo prioritario de vacunación. Además, se considera recomendable la vacunación antigripal y antineumocócica tanto en el adulto sano de menos de 60 años como en cualquier persona de cualquier edad con condición de riesgo para NAC. La vacuna de la gripe se administrará estacionalmente, mientras que la vacunación antineumocócica podrá administrarse en cualquier momento del año. Conclusiones. La vacunación frente a neumococo y gripe en el adulto puede contribuir a disminuir la carga de enfermedad por NAC y sus complicaciones asociadas. La evidencia disponible avala las indicaciones prioritarias establecidas en esta guía, y sería recomendable tratar de lograr una difusión e implementación amplia en la práctica de estas recomendaciones (AU)


Introduction. Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in adults. The annual incidence of CAP in adults in Spain ranges from 3 to 14 cases per 1,000 inhabitants. Current clinical guidelines primarily focus on the therapeutic approach to CAP rather than its prevention. The aim of this study is to develop and propose a practical guide for CAP prevention through vaccination in Spain according to available vaccines and evidence. Methods. A literature review and expert opinion. Results. Pneumococcal and influenza vaccines are the main preventive tools available against CAP. Age, chronic diseases, and immunosuppression are risk factors for pneumonia, so these populations should be a priority for vaccination. In addition, influenza and pneumococcal vaccination is considered advisable in healthy adults under 60 years of age, and anyone with risk condition for CAP, irrespective of age. The influenza vaccine will be administered seasonally, while pneumococcal vaccination can be administered at any time of the year. Conclusions. Vaccination against pneumococcus and influenza in adults can help to reduce the burden of CAP and its associated complications. The available evidence supports the priority indications set out in this guide, and it would be advisable to try to achieve a wide circulation and practical implementation of these recommendations (AU)


Subject(s)
Humans , Male , Female , Consensus Development Conferences as Topic , Vaccination/methods , Vaccination , Pneumonia/epidemiology , Pneumonia/prevention & control , Influenza Vaccines/immunology , Community-Acquired Infections/immunology
17.
Semergen ; 42(7): 464-475, 2016 Oct.
Article in Spanish | MEDLINE | ID: mdl-27641310

ABSTRACT

INTRODUCTION: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in adults. The annual incidence of CAP in adults in Spain ranges from 3 to 14 cases per 1,000 inhabitants. Current clinical guidelines primarily focus on the therapeutic approach to CAP rather than its prevention. The aim of this study is to develop and propose a practical guide for CAP prevention through vaccination in Spain according to available vaccines and evidence. METHODS: A literature review and expert opinion. RESULTS: Pneumococcal and influenza vaccines are the main preventive tools available against CAP. Age, chronic diseases, and immunosuppression are risk factors for pneumonia, so these populations should be a priority for vaccination. In addition, influenza and pneumococcal vaccination is considered advisable in healthy adults under 60 years of age, and anyone with risk condition for CAP, irrespective of age. The influenza vaccine will be administered seasonally, while pneumococcal vaccination can be administered at any time of the year. CONCLUSIONS: Vaccination against pneumococcus and influenza in adults can help to reduce the burden of CAP and its associated complications. The available evidence supports the priority indications set out in this guide, and it would be advisable to try to achieve a wide circulation and practical implementation of these recommendations.


Subject(s)
Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Mass Vaccination/methods , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Pneumonia, Viral/prevention & control , Adolescent , Adult , Aged , Community-Acquired Infections/prevention & control , Humans , Middle Aged , Seasons , Spain , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...